ArticleFrontiers in oncology2026
Past, present and future of nivolumab: new horizons in immuno-oncology.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last two years, nivolumab (an inhibitor of programmed death-protein 1, PD-1) has established itself as a cornerstone of modern-day cancer immunotherapy. The immuno-oncology field is developing at an accelerated rate, as nivolumab is progressively acting as an optimally strategic, globally diffused treatment base across a heterogeneous spectrum of malignancies. This has been driven by the accruing data on pivotal phase 3 trials that show better survival rates alongside subsequent regulatory approvals both at the national and international levels that have expanded its therapeutic indications. Meanwhile its translational and clinical impact has been increased further by expanded-access programmes and new combinatorial approaches. All these developments highlight the increasing clinical relevance of nivolumab as they also highlight the current issues in the provision of equitable access, in performing biomarker-based patient stratification, and in optimizing therapeutic sequencing in the rapidly evolving framework of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.